

# SEQUENCE LISTING

<110> Schenk, Dale B.  
Neuralab Limited

<120> Prevention and Treatment of Amyloidogenic Disease

<130> 15270J-004720US

<140> 09/201,430

<141> 1998-11-30

<150> US 60/067,740

<151> 1997-12-02

<150> US 60/080,970

<151> 1998-04-07

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 42

<212> PRT

<213> Homo sapiens

<220>

<223> human Abeta42 beta-amyloid peptide

<400> 1

Asp	Ala	Glu	Phe	Arg	His	Asp	Ser	Gly	Tyr	Glu	Val	His	His	Gln	Lys
1				5					10					15	

Leu	Val	Phe	Phe	Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	Gly	Ala	Ile	Ile
			20					25					30		

Gly	Leu	Met	Val	Gly	Gly	Val	Val	Ile	Ala
		35					40		

<210> 2

<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Abeta1-12  
peptide with carboxyl terminal Cys residue  
inserted

<400> 2  
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val Cys  
1 5 10

<210> 3  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Abeta1-5  
peptide with carboxyl terminal Cys residue  
inserted

<400> 3  
Asp Ala Glu Phe Arg Cys  
1 5

<210> 4  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Abeta33-42  
peptide with carboxyl terminal Cys residue  
inserted

<220>  
<221> MOD\_RES  
<222> (2)  
<223> Xaa = amino heptanoic acid

<400> 4

Cys Xaa Gly Leu Met Val Gly Gly Val Val Ile Ala  
1 5 10

<210> 5

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Abeta13-28  
peptide with carboxyl terminal Cys residue  
inserted and two added Gly residues

<220>

<221> MOD\_RES

<222> (1)

<223> Xaa = acetyl histidine

<400> 5

Xaa His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys  
1 5 10 15

Gly Gly Cys